Document Detail


Practical use of biologic therapy in dermatology: some considerations and checklists.
MedLine Citation:
PMID:  22398223     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Practice varies with respect to biologic therapy counseling and monitoring of biologic therapy. Because of the complexity, many physicians shy away from prescribing biologic therapy.
OBJECTIVE: To create checklists and discuss considerations behind various counseling and monitoring issues.
METHODS: The full prescribing information of infliximab, etanercept, adalimumab, golimumab, certolizumab, alefacept, ustekinumab, rituximab, and IVIg were reviewed in addition to National Psoriasis Foundation guidelines to create the checklists.
RESULTS: Considerations of counseling for biologics includes explaining benefits, relative risks of not treating or alternative therapies, consequence of risk, preventability of risk, and likelihood of risk. Considerations regarding vaccination, viral hepatitis screening, tuberculosis screening, skin cancer screening, pregnancy, and anti-nuclear antibody screening are discussed.
LIMITATIONS: Consensus is unavailable as to the extent of counseling or monitoring. This manuscript provides one perspective.
CONCLUSIONS: This article reviews monitoring and patient counseling considerations for the use of biologics in dermatology. Tables for each drug are provided with checklists for counseling and monitoring.
Authors:
Melanie Ortleb; Jacob Oren Levitt
Related Documents :
18303753 - The impact of antenatal care on pregnancy performance between adolescent girls and olde...
21538023 - Concept mapping with south asian immigrant women: barriers to mammography and solutions.
22272693 - Psychiatric disorders and psychosocial correlates of high hiv risk sexual behaviour in ...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-02-15
Journal Detail:
Title:  Dermatology online journal     Volume:  18     ISSN:  1087-2108     ISO Abbreviation:  Dermatol. Online J.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-03-08     Completed Date:  2012-07-17     Revised Date:  2012-10-04    
Medline Journal Info:
Nlm Unique ID:  9610776     Medline TA:  Dermatol Online J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2     Citation Subset:  IM    
Affiliation:
University of Nebraska Medical Center, Omaha, Nebraska, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Therapy / adverse effects*
Directive Counseling
Female
Humans
Pregnancy
Risk
Skin Diseases / therapy*
Tuberculosis, Pulmonary / chemically induced
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Trends in the use of topical over the counter products in the management of dermatologic disease in ...
Next Document:  Alopecia: a review of laser and light therapies.